Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Calquence

(KAL-kwents)
A drug used alone to treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma and adults with mantle cell lymphoma that has already been treated with at least one other therapy. Calquence is used with bendamustine and rituximab to treat adults with mantle cell lymphoma that has not been treated and who cannot receive an autologous stem cell transplant. It is also being studied in the treatment of other types of cancer. Calquence blocks a protein called BTK, which may help keep cancer cells from growing. It is a type of tyrosine kinase inhibitor. Also called acalabrutinib maleate monohydrate.
More Information
Search NCI's Dictionary of Cancer Terms